Lazertinib vs Rezivertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).
Next expected readout: December 2026 · NCT05463224 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)
Result source: NCT04487080
Rezivertinib
Marketed by Beta Pharma, Inc.
NCT03866499 · Phase 3 · status unknown
This trial randomized 369 patients to BPI-7711 or active-controlled gefitinib with full blinding of participants, care providers, investigators, and outcome assessors, testing a hard clinical endpoint (progression-free survival) that is standard for regulatory approval in NSCLC. The primary comparison was statistically significant and favored BPI-7711, with a nearly doubled median PFS and a strong hazard ratio, supporting confidence in the result.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
Reported efficacy
Progression-free survival (up to approximately 16 months): REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 (met)
Result source: NCT03866499
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lazertinib | Rezivertinib |
|---|---|---|
| PFS, median | 20.6 vs 9.7vs GefitnibNCT042488296 other results
| —Trial running · NCT06955325 |
| OS, median | 9.1bNCT040753961 other result
| —Trial running · NCT06955325 |
| ORR | 76% vs 76.1%vs GefitnibNCT042488292 other results
| —Trial running · NCT06955325 |
| Duration of response, median | 19.4 vs 8.3vs GefitnibNCT042488291 other result
| —Trial running · NCT06955325 |
PFS, median
- Lazertinib
- 20.6 vs 9.7vs GefitnibNCT04248829
6 other results
- 23.7 vs 16.6 NCT04487080
- 18.5 vs 16.6 NCT04487080
- 8.3 vs 4.2 NCT04988295
- 6.3 vs 4.2 NCT04988295
- 3.1 NCT04075396
- 4.2 NCT04075396
- Rezivertinib
- —Trial running · NCT06955325
OS, median
- Lazertinib
- 9.1bNCT04075396
1 other result
- 7.7 NCT04075396
- Rezivertinib
- —Trial running · NCT06955325
ORR
- Lazertinib
- 76% vs 76.1%vs GefitnibNCT04248829
2 other results
- 26.7% NCT04075396
- 7.7% NCT04075396
- Rezivertinib
- —Trial running · NCT06955325
Duration of response, median
- Lazertinib
- 19.4 vs 8.3vs GefitnibNCT04248829
1 other result
- 2.8 NCT04075396
- Rezivertinib
- —Trial running · NCT06955325
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lazertinib: 4 of 4 rows · Rezivertinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lazertinib |
|---|---|
| Dropout rate | 44.9%240 mga NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results78.1%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 75%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 74.5%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 80.2%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 9.7%240 mga NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results—Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence —320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 26%240 mga NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results48.7%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 35.2%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 52.1%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 32.3%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 66.7%240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence 46.2%320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 240 mga paraesthesia 39.3% rash 36.2% pruritus 26.5% NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more resultsparonychia 68.4% infusion related reaction 62% rash 61.8% NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 rash 44.6% diarrhoea 31.9% paronychia 28.6% NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 neutropenia 65.8% thrombocytopenia 59.3% infusion related reaction 54% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 infusion related reaction 56.9% neutropenia 56.2% nausea 44.6% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 240 mg anaemia 46.7% diarrhoea 46.7% aspartate aminotransferase increased 26.7% NCT04075396 · Phase 1/2 · registry result, not featured evidence 320 mg nausea 61.5% diarrhoea 53.8% arthralgia 23.1% NCT04075396 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lazertinib
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lazertinib's landscape · Rezivertinib's landscape